ReviewHealth economics review2024

Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review.

Nasrin Abulhasanbeigi Gallehzan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.